CODX - Co-Diagnostics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9041
-0.0350 (-3.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9391
Open0.9201
Bid0.0000 x 1400
Ask0.0000 x 800
Day's Range0.8222 - 0.9653
52 Week Range0.8220 - 6.6600
Volume272,113
Avg. Volume266,206
Market Cap15.384M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4740
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    Co-Diagnostics, Inc Files Q1 2019 Report on Form 10-Q and Updates Corporate Developments

    Co-Diagnostics, Inc. , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the filing of its operating results on SEC Form 10-Q for the 3 month period ending March 31, 2019 and provided updates on corporate developments.

  • GlobeNewswire6 days ago

    H.C. Wainwright and Maxim Group Estimate Nearly 95% Upside for CODX

    Analysts from H.C. Wainwright and Maxim Group have both given BDA International client company Co-Diagnostics (CODX) a “Buy” rating in the past few weeks, with an estimated price target nearly double its previous close of $1.03. The reports included an in-depth analysis of the molecular diagnostics company’s technology, the quality and novelty of their intellectual property, its validation by the LGC partnership, and solutions that it will provide for various diagnostics markets (e.g.

  • GlobeNewswire7 days ago

    CEO Today Magazine Features Exclusive Interview with Co-Diagnostics Inc CEO Dwight Egan

    The May 2019 issue of the prestigious CEO Today Magazine will include an interview with the CEO of Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, and client of BDA International. The interview provides details on a variety of subjects, including a layman’s explanation of how polymerase chain reaction (PCR) works, the PCR technologies used by the Company, and their applications (liquid biopsy/early cancer detection, AgBio production, and next generation DNA sequencing, in addition to infectious disease diagnostics).  Mr. Egan also describes how their proprietary platform lowers overheads and creates cost savings passed on to the end users.

  • Business Wire20 days ago

    Co-Diagnostics, Inc. Files Provisional Patent for Simplified Targeted NGS Library Preparation

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced today the filing of a provisional patent with the USPTO for its single-step next generation sequencing (NGS) library preparation methods and composition, claiming an exclusive privilege and/or right to practice the invention, which also embodies the use of the Company’s patented CoPrimer™ technology in the process. The technology has numerous applications in liquid biopsy and oncology, agrigenomics, and infectious diseases. NGS is a powerful DNA sequencing technology enabling the mapping or identifying of a large number of DNA fragments simultaneously.

  • GlobeNewswire25 days ago

    Diagnostics Manufacturing Facility Launches in India to Service Growing Indian Healthcare Market

    The long-awaited molecular diagnostics manufacturing facility for the Indian joint venture between Co-Diagnostics Inc. and Synbiotics Pvt Ltd has finally launched, according to news released last week. BDA International client company Co-Diagnostics first announced the formation of the CoSara Diagnostics Pvt Ltd joint venture with Synbiotics in 2017. Since that time, shareholders have been eager for any news or updates concerning the completion of the facility that was described as one of the first of its kind in India, and is expected to provide molecular diagnostics across the country of India (nearly 18% of the world’s population, and expected to grow into the world’s largest single healthcare market in the next several years).

  • Business Wirelast month

    Co-Diagnostics, Inc. CEO Inaugurates Manufacturing Joint Venture Facility

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the inauguration of its Indian joint venture facility for manufacturing in Ranoli, India. The manufacturing facility for CoSara Diagnostics Pvt Ltd (CoSara) is one of the first facilities for manufacturing molecular diagnostics in India and is intended to meet both current and future requirements for medical device manufacturing, which are expected to be implemented by the Indian government over the next few years.

  • ACCESSWIRE2 months ago

    Co-Diagnostics FY2018 Updates Include Revenue, Patents, Regulatory Clearance

    NEW YORK, NY / ACCESSWIRE / April 4, 2019 / Commercial sales of Co-Diagnostics, Inc., (CODX) products to Indian distributors commenced earlier this year, according to news released this week following the submission of their annual 10-K SEC filing for FY2018. The sales in India consisted of primer sets for the non-clinical identification of tuberculosis, malaria, and human papillomavirus (HPV), engineered using Co-Diagnostics' proprietary design process and patented CoPrimer technology, as well as other test reagents and components used in polymerase chain reaction (PCR) testing. The release did not include the amount of revenue since the sales took place in 2019, but that information should be publicly available following their Q1 SEC filing.

  • Business Wire2 months ago

    Co-Diagnostics, Inc. Reports 2018 Year-End Financial Results and Progress Updates

    Co-Diagnostics, Inc. , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the filing

  • Business Wire2 months ago

    Co-Diagnostics, Inc. to Host 1st Semiannual Distributor Conference on March 26-28

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting its 1st semiannual distributor conference on March 26-28 at the Company’s headquarters in Salt Lake City, Utah. Conference attendees already committed to attend include government, environmental testing, and private laboratory customers and distributors of the Company’s products.

  • ACCESSWIRE2 months ago

    Co-Diagnostics Sales of New Multi-Viral Test Imminent Post CE Mark

    NEW YORK, NY / ACCESSWIRE / March 13, 2019 / Co-Diagnostics, Inc., (CODX), expects to immediately begin commercializing their newly-CE marked test for Zika, dengue and chikunguna, according to news released last week. The Co-Diagnostics release announced that their new Logix Smart ZDC test meets the essential requirements of the European Community's In-Vitro Diagnostic Medical Device Directive, allowing immediate export and sales of the product to markets that accept a CE mark as valid IVD regulatory approval, with the expectation that additional sales and distribution opportunities will be created following the granting of this approval across their target markets. Last week's announcement stated that the design, development, and validation of test was completed from start to finish in under 6 months, including the entire regulatory approval process.

  • ACCESSWIRE2 months ago

    Watch These Four Healthcare Stocks Set The Standard on Thursday

    CORAL GABLES, FL / ACCESSWIRE / March 7, 2019 / The healthcare stock market has gotten off to an impressive start in the first few months of 2019, as companies in the healthcare sector work to pioneer innovative drug treatment options and care solutions for the millions of patients in need. On a near daily basis, headlines detailing a company's new drug approval or a technological breakthrough emerge, indicating to potential investors that they could benefit from paying attention to the healthcare sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), GTx Inc (GTXI), Co-Diagnostics Inc (CODX), and Novavax Inc (NASDAQ:NVAX) represent 4 healthcare companies heating up on Thursday.

  • ACCESSWIRE3 months ago

    Co-Diagnostics Creates Sales Opportunities with CE Mark Submission and Mosquito Testing Vertical

    NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Utah-based Co-Diagnostics, Inc., (CODX), has hit the ground running this year. The last week alone has brought news of expanding their revenue potential in the vector control vertical, a CE mark submission for a high-quality diagnostic with a global market that tests for multiple diseases at once, and the announcement that they are out of the woods as far as their Nasdaq listing requirements. Vector control - or mitigating organisms that transmit infectious diseases, in this case mosquitos - is an important component of slowing the spread of mosquito-borne pathogens.

  • Business Wire3 months ago

    Co-Diagnostics Completes Submission of CE Mark Registration for Zika/Dengue/Chikungunya Multiplex Test

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ZDC (multiplex Zika-dengue-chikungunya) Test technical file has been submitted for registration with the European Community, and that the in vitro diagnostic (“IVD”) is expected to be available for purchase in March 2019 in markets that accept a CE mark as valid regulatory approval.

  • Business Wire3 months ago

    Co-Diagnostics, Inc. Regains Compliance with NASDAQ Listing Standards

    Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has received written notice from the Nasdaq Stock Market (“Nasdaq”) Listing Qualifications Staff on February 19, 2019, indicating that the Company has regained compliance with the minimum stockholders’ equity requirement as set forth in Nasdaq Capital Markets Listing Rule 5550(b)(1). Nasdaq considers the matter closed. Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology.

  • Business Wire3 months ago

    Co-Diagnostics, Inc. Announces Mosquito Vector Control Training Course in the Dominican Republic

    Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that their distributor in the Dominican Republic is hosting a workshop on techniques for applying molecular diagnostics to identify disease-carrying mosquitos. The trainings will be conducted by a Co-Diagnostics representative and will include demonstrations of the Company’s polymerase chain reaction (PCR) malaria and ZDC (multiplex Zika-dengue-chikungunya) tests.

  • ACCESSWIRE3 months ago

    Co-Diagnostics Finishes Week Over 30% Higher with a Solid Balance Sheet

    NEW YORK, NY / ACESSWIRE / February 5, 2019 / Relatively thin trading and susceptibility to wider swings in trading price and volume are nothing new to most microcaps, but few companies calmly and strategically ride the wave of short-term volatility and end up on stronger footing than they started. Let's take a look at the timeline for this molecular diagnostics company, and compare where they began to where they are today. Following a few weeks of aggressive selling, CODX opened the week of January 28 at $0.96.

  • Business Wire3 months ago

    Co-Diagnostics, Inc. Announces Closing of $5.5 Million Registered Direct Offering

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the closing of its previously announced offering. In a registered direct offering, Co-Diagnostics issued and sold 3,925,716 shares of its common stock at a price of $1.40 per share, for gross proceeds of approximately $5.5 million. Maxim Group LLC acted as financial advisor to Co-Diagnostics, Inc.

  • Business Wire4 months ago

    Co-Diagnostics Announces $5.5 Million Registered Direct Offering

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,925,716 shares of its common stock, at a purchase price per share of $1.40, in a registered direct offering. The closing of the offering is expected to occur on or about February 4, 2019, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Raising The Bar On Wednesday (1/30/19)

    With the advent of new medical technologies and approaches to treating patients suffering from a myriad of diseases, news surrounding innovative companies putting their skills to the test in the healthcare industry has worked to attract investors looking for potential opportunities in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Co-Diagnostics Inc (CODX), Can-Fite BioPharma Ltd (CANF), and Eyenovia Inc (EYEN) represent four healthcare companies determined to develop and distribute the best quality healthcare options for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • ACCESSWIRE4 months ago

    Co-Diagnostics - No More Debt and Cash on the Balance Sheet

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Co-Diagnostics, Inc., (CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, capped a volatile month of trading with some positive financial news. The transaction was described by Co-Diagnostics CEO in the official announcement as beneficial to shareholders by accelerating the company's growth strategy. All preferred shares are convertible to common stock at a fixed price of $1.20/share.

  • Business Wire4 months ago

    Co-Diagnostics, Inc. Announces Elimination of Debt, Additional Capital Infusion

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the sale of $3 million of preferred shares, convertible to common stock at a fixed price of $1.20 per share. The news followed recent Company announcements of its CoPrimer™ technology platform being presented at the Plant and Animal Genome (PAG) XXVII conference, and the launch of the first private-label CoPrimer product. CoPrimer technology has been shown to offer significant advantages compared to other PCR platforms, including a substantial reduction in errors that lead to false positive results, and dramatically improved multiplex test capabilities for molecular diagnostics, including infectious disease testing, agrigenomics, liquid biopsy and NGS applications.

  • Business Wire4 months ago

    Co-Diagnostics, Inc. CoPrimer™ Platform Featured at PAG XXVII Conference

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that their CoPrimer™ platform was featured in presentations at the International Plant and Genome conference (PAG XXVII) last week in San Diego, California. The public introduction of a novel, one-step SNP genotyping methodology with scalable multiplex capability followed a joint development project over the past year to test the performance of CoPrimers in multiplexed reactions. It also coincided with a private label CoPrimer product launch by a global leader in the design and manufacture of sophisticated polymerase chain reaction (PCR) reagents and other custom oligonucleotide-based tools for applied markets.

  • ACCESSWIRE4 months ago

    Wall Street Club Release: CODX Spike Nearly 26% on 53x Avg Volume Following News of Presentation with LGC, Biosearch

    NEW YORK CITY, NEW YORK / ACCESSWIRE / January 15, 2019 / Share prices ofCo-Diagnostics, Inc., (CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, hit highs of $1.54 on Monday, January 14, nearly 26% higher than the previous close and on a healthy trading volume just shy of 1.13M – over 53 times the daily average. The movement comes after news of Co-Diagnostics' participation and presentation as a guest of LGC, Biosearch Technologies (LGC) at the 27th International Plant and Genome conference (PAG XXVII), held this week in San Diego. CODX shares followed suit as the Nasdaq Composite (IXIC) trended downward to end 2018.

  • Business Wire4 months ago

    Co-Diagnostics, Inc. to Present at PAG XXVII on January 14 in San Diego

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a Company Senior Research Scientist will be presenting research into the SNP genotyping multiplex capabilities of CoPrimers™ at the 27th International Plant and Genome conference (PAG XXVII), held in San Diego, California January 12-16, 2019. Dr. Jana Kent will speak as a guest of LGC, Biosearch Technologies (LGC), a global leader in the design, development, and manufacture of sophisticated, custom oligonucleotide-based tools and associated reagents for applied markets.

  • ACCESSWIRE5 months ago

    Co-Diagnostics Inc - End of Exciting Year, Revenues & More Excitement Ahead in 2019

    NEW YORK CITY, NY / ACCESSWIRE / December 20, 2018 / Dwight Egan, CEO of Co-Diagnostics Inc, (CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, discussed the expectation for sales before the end of 2018 in a virtual investor conference earlier this month. • February 2018: The Company announced positive results in SNP multiplex tests. Months later this was revealed to have been part of an ongoing research and development study with LGC, Biosearch and helped to set the stage for a subsequent license agreement.